publication venue for
- IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bacteraemia cohort.. 76:385-395. 2021
- Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates.. 75:859-867. 2020
- Novel transferable erm(46) determinant responsible for emerging macrolide resistance in Rhodococcus equi.. 71:1746-1746. 2016
- Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study.. 71:3585-3587. 2016
- Novel transferable erm(46) determinant responsible for emerging macrolide resistance in Rhodococcus equi.. 70:3184-3190. 2015
- Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection.. 70:3061-3069. 2015
- The membrane as a target for controlling hypervirulent Clostridium difficile infections.. 68:806-815. 2013
- Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP).. 67:609-617. 2012
- In vitro antimicrobial studies of silver carbene complexes: activity of free and nanoparticle carbene formulations against clinical isolates of pathogenic bacteria.. 67:138-148. 2012
- Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations.. 66:1773-1776. 2011
- A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents.. 62:1037-1045. 2008
- In vivo transfer of high-level mupirocin resistance from Staphylococcus epidermidis to methicillin-resistant Staphylococcus aureus associated with failure of mupirocin prophylaxis.. 56:1166-1168. 2005
- Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections.. 54:549-552. 2004
- The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden.. 53:102-104. 2004